<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03822052</url>
  </required_header>
  <id_info>
    <org_study_id>ME 19 004</org_study_id>
    <nct_id>NCT03822052</nct_id>
  </id_info>
  <brief_title>The Use of D5LR Versus LR for Induction of Labor and Time to Delivery in Multiparous and Primiparous Patient's With Favorable and Unfavorable Bishop's Scores</brief_title>
  <official_title>A Randomized Controlled Trial Comparing D5LR to LR for Induction of Labor and Time to Delivery in Multiparous and Primiparous Patient's With Favorable and Unfavorable Bishop's Scores</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascension Genesys Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascension Genesys Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, the optimum IV fluid for induction of labor is unknown. The goal of this study is
      to determine the optimum fluid for induction of labor, D5LR versus LR. The investigators
      hypothesize that patients assigned to the D5LR group will have a shorter induction of labor
      when compared to patient's in the LR group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction of labor is increasingly common in the United States, as the overall rate has
      increased from 9.5% in 1990 to 22.1% in 2006 with the goal to stimulate contractions prior to
      the onset of spontaneous labor. Cesarean delivery rates are also at an all-time high in the
      U.S., with more than 32% of patients being delivered by Cesarean in 2009. One of the most
      common indications for Cesarean section is a prolonged labor course. Patient's with a
      prolonged labor course are also at risk for infections, including chorioamnionitis and
      endometritis, as well as an increased risk of postpartum hemorrhage. There is a lack of
      information on ways to help shorten labor to potentially minimize these risks.

      The uterus is comprised of skeletal muscle, and labor has been likened to prolonged rigorous
      exercise. While oral hydration has been endorsed by ACOG for low-risk women in spontaneous
      labor, solid foods should be avoided. In turn, women with a prolonged induction or labor may
      benefit from glucose supplementation via IV fluids.

      The DEXTRONS study, J. Pare et al., looked at supplementation of D5LR versus normal saline in
      nulliparous patients who presented for a favorable induction of labor. This study showed a
      significant reduction in active labor time in the D5LR group versus the normal saline group.

      Currently, at Genesys Regional Medical Center, lactated ringers is the preferred IV fluid for
      patients presenting for induction of labor. This study will randomly assign patients to D5LR
      versus lactated ringers and examine the length of time from induction to delivery to
      determine if glucose supplementation has an effect on reducing length of induction in both
      nulliparous and multiparous patients for either a favorable induction of labor or an
      induction for post-dates. Secondary outcomes will include Apgar scores, need for special care
      nursery/NICU admissions, and mode of delivery. The study will begin in January 2019 and
      continue through July 2019. Patients who presented to labor and delivery and consent to be
      included in the study will be randomized to each group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Actual">December 19, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of induction</measure>
    <time_frame>492 min +/- 35 min</time_frame>
    <description>Time from start of labor induction to delivery of infant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of Active Labor</measure>
    <time_frame>4 hours +/- 3 hours</time_frame>
    <description>time from 6 cm dilation until delivery of infant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar Scores</measure>
    <time_frame>492 min +/- 35 min</time_frame>
    <description>validated measure of infant health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of Delivery</measure>
    <time_frame>492 min +/- 35 min</time_frame>
    <description>Cesarean section vs SVD vs OVD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal ICU admissions</measure>
    <time_frame>24 hours after delivery</time_frame>
    <description>ICU or special care nursery admissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for respiratory support</measure>
    <time_frame>24 hours after delivery</time_frame>
    <description>Neonatal need for respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfer to tertiary care center</measure>
    <time_frame>24 hours after delivery</time_frame>
    <description>neonatal need for transfer to higher level NICU</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>Primiparous Patient, Unfavorable Bishop Score</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient to receive D5LR or LR at 125 cc/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primiparous Patient, Favorable Bishop Score</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient to receive D5LR or LR at 125 cc/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiparous patient, Unfavorable Bishop Score</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient to receive D5LR or LR at 125 cc/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiparous patient, Favorable Bishop Score</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient to receive D5LR or LR at 125 cc/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactated ringers</intervention_name>
    <description>IV fluid</description>
    <arm_group_label>Multiparous patient, Favorable Bishop Score</arm_group_label>
    <arm_group_label>Multiparous patient, Unfavorable Bishop Score</arm_group_label>
    <arm_group_label>Primiparous Patient, Favorable Bishop Score</arm_group_label>
    <arm_group_label>Primiparous Patient, Unfavorable Bishop Score</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>5% dextrose lactated ringers</intervention_name>
    <description>IV fluid</description>
    <arm_group_label>Multiparous patient, Favorable Bishop Score</arm_group_label>
    <arm_group_label>Multiparous patient, Unfavorable Bishop Score</arm_group_label>
    <arm_group_label>Primiparous Patient, Favorable Bishop Score</arm_group_label>
    <arm_group_label>Primiparous Patient, Unfavorable Bishop Score</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women, age 18 - 45, that were admitted for induction of labor without any
             co-morbid conditions and their respective newborns with

          -  Induction of labor

          -  Singleton pregnancies

          -  Vertex presentation

          -  Pregnancies at 39 0/7 weeks gestation - 41 6/7 weeks gestation

          -  All races/ethnicities

        Exclusion Criteria:

          -  Multifetal gestations

          -  Noncephalic presentation

          -  Preexisting medical conditions:

          -  Maternal cardiac disease

          -  Lung diseases

          -  Chronic hypertension

          -  Pregestational or gestational diabetes

          -  gHTN or Pre-Eclampsia

          -  medical indication for induction of labor (olighydramnios, IUGR)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ascension Genesys Hospital</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fong A, Serra AE, Caballero D, Garite TJ, Shrivastava VK. A randomized, double-blinded, controlled trial of the effects of fluid rate and/or presence of dextrose in intravenous fluids on the labor course of nulliparas. Am J Obstet Gynecol. 2017 Aug;217(2):208.e1-208.e7. doi: 10.1016/j.ajog.2017.03.010. Epub 2017 Mar 18.</citation>
    <PMID>28322776</PMID>
  </reference>
  <reference>
    <citation>Sharma C, Kalra J, Bagga R, Kumar P. A randomized controlled trial comparing parenteral normal saline with and without 5% dextrose on the course of labor in nulliparous women. Arch Gynecol Obstet. 2012 Dec;286(6):1425-30. doi: 10.1007/s00404-012-2485-1. Epub 2012 Aug 4.</citation>
    <PMID>22865033</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee on Practice Bulletins -- Obstetrics. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol. 2009 Aug;114(2 Pt 1):386-97. doi: 10.1097/AOG.0b013e3181b48ef5. Review.</citation>
    <PMID>19623003</PMID>
  </reference>
  <reference>
    <citation>Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017 Oct;130(4):e168-e186. doi: 10.1097/AOG.0000000000002351.</citation>
    <PMID>28937571</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee Opinion No. 761: Cesarean Delivery on Maternal Request. Obstet Gynecol. 2019 Jan;133(1):e73-e77. doi: 10.1097/AOG.0000000000003006.</citation>
    <PMID>30575678</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee Opinion No. 766: Approaches to Limit Intervention During Labor and Birth. Obstet Gynecol. 2019 Feb;133(2):e164-e173. doi: 10.1097/AOG.0000000000003074.</citation>
    <PMID>30575638</PMID>
  </reference>
  <reference>
    <citation>Philipson EH, Kalhan SC, Riha MM, Pimentel R. Effects of maternal glucose infusion on fetal acid-base status in human pregnancy. Am J Obstet Gynecol. 1987 Oct;157(4 Pt 1):866-73.</citation>
    <PMID>3314516</PMID>
  </reference>
  <reference>
    <citation>Par√© J, Pasquier JC, Lewin A, Fraser W, Bureau YA. Reduction of total labor length through the addition of parenteral dextrose solution in induction of labor in nulliparous: results of DEXTRONS prospective randomized controlled trial. Am J Obstet Gynecol. 2017 May;216(5):508.e1-508.e7. doi: 10.1016/j.ajog.2017.01.010. Epub 2017 Jan 30.</citation>
    <PMID>28153654</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ascension Genesys Hospital</investigator_affiliation>
    <investigator_full_name>Katelyn Hartung</investigator_full_name>
    <investigator_title>DO, Postgraduate Year 3</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 10, 2020</submitted>
    <returned>May 28, 2020</returned>
    <submitted>June 2, 2020</submitted>
    <returned>June 15, 2020</returned>
    <submitted>June 23, 2020</submitted>
    <returned>July 6, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

